Literature DB >> 12444548

Rapid tumor development and potent vascularization are independent events in carcinoma producing FGF-1 or FGF-2.

Clotilde Billottet1, Bassam Janji, Jean-Paul Thiery, Jacqueline Jouanneau.   

Abstract

FGF-1 and FGF-2 are pleiotropic growth factors for many cell types, operating through the activation of specific transmembrane FGF receptors (FGFRs). The role of these factors in tumor progression was investigated, with specific discrimination between their autocrine and non autocrine cellular activity. The rat bladder carcinoma NBT-II cells were engineered to produce FGF-1 or 18 kDa FGF-2 in the presence or absence of their specific receptor. Non-autocrine cells that produced FGF-1 or FGF-2 but lacked FGFRs were epithelial and reminiscent of the parental NBT-II cells. Whilst autocrine cells, which both constitutively produced and secreted the growth factor and expressed FGFRs, had a highly invasive mesenchymal phenotype. Correspondingly, the autocrine cells were highly tumorigenic in vivo compared to the parental and non-autocrine cells, which correlated with the increased production of uPAR and active uPA and increased in vitro invasive potential. Although all cells produced VEGF, only tumors derived from cells that produced FGF-1 or FGF-2 were highly vascularized, suggesting that these two growth factors could be involved in the angiogenic process by activating host endothelial cells. As a result of activation of the FGFR in autocrine cells, changes in cell morphology and an increase in the invasive and tumorigenic properties were observed, however no in vitro or in vivo differential functions between FGF-1 and FGF-2 could be identified in this system. In conclusion, our data demonstrates that rapid tumor development is not dependent upon increased tumor vascularization, suggesting that 'basal' angiogenesis, probably mediated by VEGF, is sufficient to support tumor growth.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12444548     DOI: 10.1038/sj.onc.1205935

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

1.  Intermedin promotes hepatocellular carcinoma cell proliferation through the classical Wnt signaling pathway.

Authors:  Hai Shang; Zhi Qiang Hao; Xi Bo Fu; Xiang Dong Hua; Zuo Hong Ma; Fu Lu Ai; Zhao Qiang Feng; Kun Wang; Wen Xin Li; Bo Li
Journal:  Oncol Lett       Date:  2018-02-13       Impact factor: 2.967

2.  Early effects of combretastatin A4 phosphate assessed by anatomic and carbogen-based functional magnetic resonance imaging on rat bladder tumors implanted in nude mice.

Authors:  Carole D Thomas; Christine Walczak; Julia Kaffy; Renée Pontikis; Jacqueline Jouanneau; Andreas Volk
Journal:  Neoplasia       Date:  2006-07       Impact factor: 5.715

3.  Targets of fibroblast growth factor 1 (FGF-1) and FGF-2 signaling involved in the invasive and tumorigenic behavior of carcinoma cells.

Authors:  Clotilde Billottet; Nadia Elkhatib; Jean-Paul Thiery; Jacqueline Jouanneau
Journal:  Mol Biol Cell       Date:  2004-07-28       Impact factor: 4.138

4.  Systemic sclerosis-endothelial cell antiangiogenic pentraxin 3 and matrix metalloprotease 12 control human breast cancer tumor vascularization and development in mice.

Authors:  Francesca Margheri; Simona Serratì; Andrea Lapucci; Chillà Anastasia; Betti Giusti; Marco Pucci; Eugenio Torre; Francesca Bianchini; Lido Calorini; Adriana Albini; Agostina Ventura; Gabriella Fibbi; Mario Del Rosso
Journal:  Neoplasia       Date:  2009-10       Impact factor: 5.715

5.  Resistin promotes the expression of vascular endothelial growth factor in ovary carcinoma cells.

Authors:  Li Pang; Yi Zhang; Yu Yu; Shulan Zhang
Journal:  Int J Mol Sci       Date:  2013-05-07       Impact factor: 5.923

6.  Adrenomedullin Up-regulates the Expression of Vascular Endothelial Growth Factor in Epithelial Ovarian Carcinoma Cells via JNK/AP-1 Pathway.

Authors:  Qingqing Chen; Pan Chen; Xiaoyan Pang; Yanling Hu; Yi Zhang
Journal:  Int J Gynecol Cancer       Date:  2015-07       Impact factor: 3.437

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.